BONE MARROW FAILURE SYNDROME 4
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
Myb-like, SWIRM, and MPN domains 1 (MYSM1) deficiency: Genotoxic stress-associated bone marrow failure and developmental aberrations.
|
28115216 |
2017 |
BONE MARROW FAILURE SYNDROME 4
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
An in vivo genetic reversion highlights the crucial role of Myb-Like, SWIRM, and MPN domains 1 (MYSM1) in human hematopoiesis and lymphocyte differentiation.
|
26220525 |
2015 |
BONE MARROW FAILURE SYNDROME 4
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
MYSM1 is mutated in a family with transient transfusion-dependent anemia, mild thrombocytopenia, and low NK- and B-cell counts.
|
24288411 |
2013 |
BONE MARROW FAILURE SYNDROME 4
|
0.600 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
BONE MARROW FAILURE SYNDROME 4
|
0.600 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
Bone marrow hypocellularity
|
0.400 |
Biomarker
|
phenotype |
GENOMICS_ENGLAND |
Deubiquitinase MYSM1 Regulates Innate Immunity through Inactivation of TRAF3 and TRAF6 Complexes.
|
26474655 |
2015 |
Bone marrow hypocellularity
|
0.400 |
Biomarker
|
phenotype |
HPO |
|
|
|
Pancytopenia
|
0.310 |
Biomarker
|
disease |
BEFREE |
Myb-like, SWIRM, and MPN domains 1 (MYSM1) deficiency: Genotoxic stress-associated bone marrow failure and developmental aberrations.
|
28115216 |
2017 |
Pancytopenia
|
0.310 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Deubiquitinase MYSM1 Regulates Innate Immunity through Inactivation of TRAF3 and TRAF6 Complexes.
|
26474655 |
2015 |
Immunologic Deficiency Syndromes
|
0.300 |
Biomarker
|
group |
GENOMICS_ENGLAND |
Deubiquitinase MYSM1 Regulates Innate Immunity through Inactivation of TRAF3 and TRAF6 Complexes.
|
26474655 |
2015 |
Malar flattening
|
0.300 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Deubiquitinase MYSM1 Regulates Innate Immunity through Inactivation of TRAF3 and TRAF6 Complexes.
|
26474655 |
2015 |
Neurodevelopmental delay
|
0.300 |
Biomarker
|
phenotype |
GENOMICS_ENGLAND |
Deubiquitinase MYSM1 Regulates Innate Immunity through Inactivation of TRAF3 and TRAF6 Complexes.
|
26474655 |
2015 |
Diabetic Retinopathy
|
0.110 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association study of diabetic retinopathy in a Taiwanese population.
|
21310492 |
2011 |
Diabetic Retinopathy
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
Using statistical models, we selected a total of 12 SNPs with P-values <1 × 10(-6) that were associated with DR. After controlling for diabetes duration and hemoglobin A(1C), 9 of the 12 SNPs located on 5 chromosomal regions were found to be associated with DR. Five loci not previously associated with DR susceptibility were identified in and around the following genes: MYSM1 (Myb-like, SWIRM, and MPN domains 1) located on chromosome 1p (odds ratio [OR], 1.50; 95% confidence interval [CI], 1.03-2.20); PLXDC2 (plexin domain-containing 2) located on the chromosome 10p (OR, 1.67; 95% CI, 1.06-2.65); ARHGAP22 (Rho GTPase-activating protein 22) located on chromosome 10q (OR, 1.65; 95% CI, 1.05-2.60); and HS6ST3 (heparan sulfate 6-O-sulfotransferase 3) located on chromosome 13q (OR, 2.33; 95% CI, 1.13-4.77).
|
21310492 |
2011 |
Diabetic Retinopathy
|
0.110 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study of diabetic retinopathy in a Taiwanese population.
|
21310492 |
2011 |
Anemia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Eczema
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Leukopenia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Dry skin
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Low set ears
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Midface retrusion
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Rhizomelia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Dry Skin, CTCAE
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Recurrent respiratory infections
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Decreased antibody level in blood
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|